TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02605174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Description: One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Description: One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Description: One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets to match lasmiditan doses.
Study: NCT01833455

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PVC Suppression using Flecainide
Description: Flecainide will be administered to result in a reduction in PVC burden.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PVC Suppression using Flecainide
Description: Flecainide will be administered to result in a reduction in PVC burden.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No PVC Suppression using Placebo
Description: Placebo (sugar pills) will be given to result in no alteration in PVC burden.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No PVC Suppression using Placebo
Description: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Study: NCT04301206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
Study: NCT04598594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch, Nicotine
Description: Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patch, Placebo
Description: Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
Study: NCT02765594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: 200mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160mg qd
Study: NCT04193761

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: taurine level
Description: Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: taurine level
Description: Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
Study: NCT02765594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160mg qd
Study: NCT00562094

Intervention type: DRUG
Intervention: Pantoprazole
Description: This was an observational study. Therefore, the physician decided about dosage according to individual needs.
Study: NCT01121627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: A 12 week computerized cognitive training at home with the Attengo™ software program.
Study: NCT01824823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT01600482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELT ACD
Description: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
Study: NCT01730456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, up to 104 weeks
Study: NCT01448941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary extraarticular plate fixation
Description: Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary arthrodesis
Description: Primary arthrodesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary arthrodesis TMT 2 and 3
Description: Primary arthrodesis TMT 2 and 3 when instability is present

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary arthrodesis TMT 2 and 3
Description: Primary arthrodesis TMT 2 and 3 when instability is present
Study: NCT03723031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
Study: NCT03293875

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Encuentro
Description: a behavioral intervention designed to increase HIV testing rates and reduce behaviors that place individuals who use drugs at risk of contracting HIV

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Encuentro
Description: a behavioral intervention designed to increase HIV testing rates and reduce behaviors that place individuals who use drugs at risk of contracting HIV
Study: NCT01128959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Carbamazepine (IV CBZ)
Description: 10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
Study: NCT04347473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilumya Injectable Product
Description: IL-23 injection
Study: NCT02076269

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Patients are receiving no treatment in this study and there is no investigational product involved
Study: NCT03349645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of AMPION™
Description: 4 mL injection of AMPION™
Study: NCT01174277

Intervention type: OTHER
Intervention: Collection of blood sample
Description: Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
Study: NCT01686750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated care centers
Study: NCT02378012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Intervention
Description: Receive access to Netflix, Spotify, and Skype applications

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Receive access to Netflix, Spotify, and Skype applications

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Receive iPad and instruction manuals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00521391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allez Hop
Description: a tailored physical activity intervention involving moderate-intensity exercise
Study: NCT03619928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: 20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Massotherapy
Description: A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
Study: NCT03496233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]
Description: Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
Study: NCT01133405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Oral capsules
Study: NCT03294967

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: As in group descriptions
Study: NCT01133405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Oral capsules
Study: NCT03294967

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E
Description: As in group descriptions
Study: NCT01133405

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study: NCT03473717

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic method
Description: * Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~* Insert the hysterometer to measure the uterus depth.~* Locate the uterine depth on the inserter tube.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct method
Description: * Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~* Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity
Study: NCT01414101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS CRP Rx or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS CRP Rx or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS CRP Rx or Placebo
Study: NCT03145792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seeking Safety
Description: Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Pathological Gambling
Description: Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
Study: NCT00086281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (P)
Description: Placebo Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (P)
Description: Placebo Oral Solution
Study: NCT04467450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
Study: NCT05266872

Intervention type: OTHER
Intervention: Observational study with sample and data collection
Description: Observational study with sample and data collection
Study: NCT00512252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study: NCT05404347

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequencing
Description: NGS is carried out on DNA isolated from paraffin embedded tissue
Study: NCT00043017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI/MRS
Description: Serial MRI studies evaluated for prognostic properties related to therapeutic response.
Study: NCT01059825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
Study: NCT05877833

Intervention type: OTHER
Intervention: Vibrancy Assessment
Description: Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
Study: NCT02985554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
Study: NCT01824901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study: NCT00512252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study: NCT00043017

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gadopentetate dimeglumine
Description: Imaging agent used for contrast enhancement in each of the MRIs.
Study: NCT00512252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT02448069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
Study: NCT03732807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Induction Dose
Description: Oral tablets taken once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Induction Dose
Description: Oral tablets taken once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Induction Dose
Description: Oral tablets taken once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #1
Description: Oral tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #1
Description: Oral tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #1
Description: Oral tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #1
Description: Oral tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #2
Description: Oral tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #2
Description: Oral tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Maintenance Dose #3
Description: Oral tablets taken QD
Study: NCT04467450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl Prednisolonate
Description: ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
Study: NCT01908907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA oil
Description: Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: (MCT) Control oil
Description: Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
Study: NCT03166137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Description: Radiation by carbon dioxide laser
Study: NCT03732807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets taken QD
Study: NCT00686595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg IV infusion.
Study: NCT01184885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD
Description: * Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are \< 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
Study: NCT03166137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Device using cooling effect
Study: NCT02365116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Description: Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
Study: NCT03337269

Intervention type: OTHER
Group type: OTHER
Intervention: Educational video
Description: Approximately 7 minute video on the HPV vaccine

Intervention type: OTHER
Group type: OTHER
Intervention: Educational handout
Description: One page handout on the HPV vaccine

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control
Study: NCT00660907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
Study: NCT02701777

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STDP
Description: Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STDP
Description: Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training
Description: The participant will be asked to perform exercises using their hands and arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The participant will be asked to perform exercises using their hands and arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The participant will be asked to perform exercises using their hands and arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham STDP
Description: Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.

Intervention type: OTHER
Group type: OTHER
Intervention: Multisite-STDP
Description: Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
Study: NCT02199951

Intervention type: DRUG
Intervention: Dihydroartemisinin and piperaquine
Description: Antimalarial
Study: NCT01069263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: 60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMSO
Description: 50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.